Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) is a rare neurodegenerative disease caused by mutations in the Cln2 gene that leads to deficiency or loss of function of the tripeptidyl peptidase 1 (TPP1) enzyme. TPP1 deficiency is known to cause the accumulation of autofluoroscent lipid-protein pigments in brain. Similar to other neurodegenerative disorders, LINCL is also associated with neuroinflammation and neuronal damage. Despite investigations, no effective therapy is currently available for LINCL. Therefore, we administered gemfibrozil (gem), an food and drug administration (FDA)-approved lipid-lowering drug, which has been shown to stimulate lysosomal biogenesis and induce anti-inflammation, orally, at a dose of 7.5 mg/kg body wt/day to Cln2 (À/À) mice. We observed that gem-fed Cln2 (À/À) mice lived longer by more than 10 weeks and had better motor activity compared to vehicle (0.1% Methyl cellulose) treatment. Gem treatment lowered the burden of storage materials, increased anti-inflammatory factors like SOCS3 and IL-1Ra, up-regulated anti-apoptotic molecule like phospho-Bad, and reduced neuronal apoptosis in the brain of Cln2 (À/À) mice. Collectively, this study reinforces a neuroprotective role of gem that may be of therapeutic interest in improving the quality of life in LINCL patients.
Lysosomes are membrane-bound organelles containing several acid hydrolases that are responsible for degradation of lipid, protein, carbohydrates, and nucleic acids (De Duve and Wattiaux 1966) . Defects/deficiencies in almost any of them result in accumulation of undigested/partially digested material in the lysosomes and form the basis of numerous lysosomal storage disorders (LSDs) (De Duve and Wattiaux 1966; Perez-Sala et al. 2009 ). Late Infantile Neuronal Ceroid Lipofuscinosis (Jansky-Bielschowsky disease, LINCL, Type 2) is one form of NCL that is caused by too mutations in the Cln2 gene. These mutations lead to deficiency and/or loss of function of tripeptidyl tripeptidase I (a 46 kDa pepstatin insensitive lysosomal protease), resulting in the accumulation of autofluorescent materials in the brain (Lane et al. 1996; Sleat et al. 1997) . LINCL typically produces symptoms at the age of 2-4 years, progresses rapidly and ends in death between ages 8-10 as a result of a dramatic decrease in the number of neurons and other cells (Lane et al. 1996; Sleat et al. 1997) . Therefore, increasing lifespan and/or improving the quality of life in patients with LINCL or other NCLs are an important area of research. However, despite years of investigations, no established treatment or drugs are available for this disease; all approaches are merely supportive or symptomatic, indicating an urgent need for novel therapeutic approaches (Chang et al. 2008) .
Several studies conclude that neuro-inflammation and induction of apoptotic pathways can be attributed to the neuronal damage in most forms of NCL, including LINCL (Puranam et al. 1997; Dhar et al. 2002; Kohan et al. 2011; Geraets et al. 2016) . Although inflammation is not the initiating factor in LINCL, glia-mediated sustained inflammatory response is believed to contribute to disease progression (Macauley et al. 2014; Cooper et al. 2015) . Gemfibrozil (gem), an FDAapproved lipid-lowering drug, is known to reduce the level of triglycerides in the blood circulation and decrease the risk of hyperlipidemia (Rubins and Robins 1992; Rubins et al. 1999; Robins et al. 2001) . However, a number of recent studies from us and others reveal that apart from its lipid-lowering effects, gem can also regulate many other signaling pathways responsible for inflammation, switching of T-helper cells, cell-to-cell contact, migration, oxidative stress, and lysosomal biogenesis (Pahan et al. 2002; Dasgupta et al. 2007; Jana et al. 2007; Roy and Pahan 2009; Corbett et al. 2012; Ghosh and Pahan 2012a; Ghosh et al. 2012 Ghosh et al. , 2015 Jana and Pahan 2012) .
Here, we investigated the therapeutic efficacy of gem in mouse model of LINCL. Behavioral analysis and survival studies on Cln2 (À/À) mice showed increased longevity and improvement of motor behavior in gem-treated animals compared to vehicle (0.1% methyl cellulose)-treated controls. The burden of storage materials and neuronal apoptosis were also found to be partially reduced in gem-treated animals with increase in levels of phospho-Bad (pBad), an anti-apoptotic molecule. Furthermore, levels of anti-inflammatory factors like SOCS3 and IL-1Ra were found to be elevated in gem-treated animals. Taken together, this study indicates a neuroprotective role of gem in Cln2 (À/À) animals. used in different treatment groups. Gem (7.5 mg/kg body wt/day) was dissolved in dimethylsulfoxide followed by dilution in 0.1% methyl cellulose (MeC). Cln2 (À/À) mice were either not fed (Ununtreated group), gavaged with 0.1% MeC (vehicle-treated group), or gavaged with gem (gem-treated group) for 8 weeks for biochemical studies. Similar treatment regimen was followed as long as the animals are not considered to be morbid as described above for survival study. Here, 40 mice (20 male and 20 female) were used per group and animals (4-week-old) were randomly selected for any group.
Materials and methods

Reagents and antibodies
Locomotor activity
Locomotor activities were measured in Cln2 (À/À) mice after 8 weeks of gem treatment using Digiscan Monitor (Omnitech Electronics, Inc., Columbus, OH, USA) as described by us (Ghosh et al. , 2009 Khasnavis and Pahan 2014) . This Digiscan Monitor records basic locomotion parameters, such as horizontal activity, total distance traveled, movement time, rest time, etc. as well as stereotypy, behavior that is directly controlled by striatum. Briefly, mice were removed directly from their cages and gently placed nose first into a specified corner of the open-field apparatus and after release, data acquisition began every five min interval.
DIGISCAN software was used to analyze and store horizontal and vertical activity data, which were monitored automatically by infrared beams. Here, 12 animals were used per group. After openfield tests, six of these mice (n = 6) were perfused for immunohistochemical analysis and four mice (n = 4) were used for Western blot analysis.
Immunohistochemistry and cell counting
After 8 weeks of treatment, mice were sacrificed and their brains fixed, embedded, and processed. Sections (30 lm) were made from different brain regions (motor cortex and striatum) using a Leica Cryostat and immunofluorescence staining on fresh frozen sections was performed as described Roy et al. 2015 Roy et al. , 2016 . Briefly, before adding blocking buffer (2% bovine serum albumin in phosphate-buffered saline), sections were incubated in 100 mM glycine for 20 min for reducing autofluorescence. For details on antibody concentrations, please see Table 1 . The samples were mounted and observed under Olympus IX41 (Waltham, MA, USA) fluorescence microscope. Counting analysis was performed using the Olympus Microsuite V software (Waltham, MA, USA) for imaging applications with the help of touch counting module Roy et al. 2015) . After acquiring images under 20 9 objective lens, images were further analyzed as follows. Before counting cells, the entire image area was calibrated with the help of a rectangular box available in the touch counting panel. Once the area of the image was measured, touch counting program was applied to count number of fluorescent signals using simple mouse click method. Next, the total number of signals in a given area was divided by the total area of the image and presented as number of cells per square millimeter unit.
Detection of storage materials
It was performed by monitoring subunit c of mitochondrial ATP synthase (SCMAS) by immunofluorescence. Please see Table 1 for details on antibody dilutions. DAPI was used to monitor nucleus. SCMAS-associated fluorescence intensity was quantified by using the Olympus Microsuite V software. Briefly, captured images were opened in the infinity image viewer and the contour was drawn around the granules to obtain the fluorescence intensity.
Immunoblot analysis
After 8 weeks of treatment, mice were sacrificed and cortex and striatum regions were isolated, homogenized in ristocetin-induced platelet agglutination buffer (150 mM sodium chloride, 1.0% NP-40 or Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0), supernatant was taken and protein was estimated by BioRad protein assay. Equal amounts of protein from the tissue extract were separated in 12% or 15% Bis-Tris gels and proteins were transferred onto a nitrocellulose membrane (Bio-Rad) using the Thermo-Pierce Fast Semi-Dry Blotter Roy et al. 2015 Roy et al. , 2016 . The membrane was then washed for 15 min in TBS plus Tween 20 (TBST) and blocked for 1 h in TBST containing bovine serum albumin. Next, membranes were incubated overnight at 4°C under shaking conditions with the antibodies for the following proteins: b-Actin, IL-1Ra, phospho-Bad, and SOCS3. Please see Table 1 for details on antibody dilutions. The next day, membranes were washed in TBST for 1 h, incubated in secondary antibodies against primary antibody hosts (all 1 : 10 000; Jackson ImmunoResearch) for 1 h, washed for one more h and visualized under the Odyssey â Infrared Imaging System (Li-COR, Lincoln, NE, USA).
Statistical analysis
All values are expressed as means AE SEM. One-way ANOVA followed by Tukey's or Scheff e's post hoc tests, Student's t-tests and Kaplan-Meier survival estimators (v 2 ) were used for data analyses, using SPSS 19 (Armonk, NY, USA).
Results
Gem treatment prolongs the lifespan in Cln2
(À/À) mice Cln2 (À/À) mouse serves as an important animal model for testing new therapeutic approaches against LINCL (Sleat et al. 2004 Cabrera-Salazar et al. 2007; Chang et al. 2008) . Usually, LINCL progresses rapidly, ending in death between ages 8 and 10 (Sleat et al. 1997; Sohar et al. 1999) . Similarly, Cln2
(À/À) mice also die within 140 days (Sleat et al. 2004) . Therefore, at first, we examined whether oral gem treatment was capable of increasing the lifespan of Cln2 (À/À) mice. Earlier, we have demonstrated that after oral administration, gem enters into the CNS (Dasgupta et al. 2007) . Mice were treated daily with gem (7.5 mg/kg body weight/day) via gavage from 4 weeks of age. Since gem was solubilized in 0.1% methyl cellulose, one group of Cln2 (À/À) mice also received 0.1% methyl cellulose as vehicle. Untreated Cln2 (À/À) male and female mice started dying from 95 days and within 137 days, all Cln2 (À/À) mice died (Fig. 1a) . In terms of survival, we did not see any difference between male and female Cln2 (À/À) mice. However, gemtreated Cln2
(À/À) mice survived until 204 days, suggesting that gem is capable of increasing the lifespan of Cln2 (À/À) mice by more than 2 months (Fig. 1a) . On the other hand, all vehicle-treated mice died within 150 days (Fig. 1a) , suggesting very mild protection by vehicle only. These results are also supported by mean survival days of each group of mice (Fig. 1b) .
Gem treatment improves motor behavior in Cln2
(À/À) mice
Together with increase in longevity, another therapeutic goal of neuroprotection for LINCL patients is to decrease functional impairment. Therefore, to examine whether gem increases not only longevity but also improves motor behavior in Cln2 (À/À) mice, we monitored locomotor activities. Locomotor activities were monitored 8 weeks after gem treatment. Cln2
(À/À) mice exhibited marked decrease in horizontal activity (Fig. 2a) , movement time (Fig. 2b) , number of movement (Fig. 2c) , total distance traveled (Fig. 2d) , and stereotypy counts (Fig. 2e ) as compared to WT mice. On the other hand, the rest time was more in
Cln2
(À/À) mice than WT mice (Fig. 2f) . However, oral administration of gem significantly improved locomotor activities in Cln2 (À/À) mice (Fig. 2a-f ).
Gem treatment lowers the burden of storage material in the brain of Cln2 (À/À) mice
One of the common characteristics of lysosomal storage disorders including LINCL is the accumulation of autofluorescent inclusion bodies in all tissues including the brain (Hachiya et al. 2006; Boustany 2013) . Recently, we delineated that gemfibrozil is capable of stimulating lysosomal biogenesis via peroxisome proliferator-activated receptor alpha (PPARa)-mediated transcriptional up-regulation of transcription factor EB (TFEB) (Ghosh et al. 2015) . Since gem treatment prolongs the lifespan and improves the motor behavior of Cln2 (À/À) mice, we examined whether gem treatment could reduce the load of storage material in vivo in the motor cortex. As expected, we observed marked increase in SCMAS accumulation in the motor cortex of Cln2
mice as compared to WT mice ( Fig. 3a and b) . However, gem treatment of Cln2 (À/À) mice led to significant decrease in SCMAS ( Fig. 3a and b) . These results were specific as vehicle treatment did not result in such decrease in storage materials ( Fig. 3a and b) .
Gem treatment prevents neuronal apoptosis in the brain of Cln2 (À/À) mice
As seen in other neurodegenerative disorders (Cotman and Anderson 1995; Saha and Pahan 2006) , apoptosis is also responsible for neuronal degeneration in LINCL (Lane et al. 1996; Puranam et al. 1997; Dhar et al. 2002) . Therefore, we examined whether gem treatment was capable of suppressing neuronal apoptosis in the CNS of Cln2 (À/À) mice. It is evident from Fig. 4a and b that NeuN-positive neurons underwent apoptosis in the motor cortex of Cln2 (À/À) mice. However, oral treatment of gem strongly inhibited neuronal apoptosis in vivo in the motor cortex ( Fig. 4a and b) . These results are specific as vehicle (0.1% methyl cellulose) treatment did not suppress neuronal apoptosis (Fig. 4a and  b) . Although Bcl-2-associated death promoter (BAD) is an apoptotic molecule, phosphorylation of BAD is known to support cell survival (Datta et al. 1999 (Datta et al. , 2002 . Therefore, we examined the level of phospho-BAD (P-BAD) in the motor cortex of Cln2 (À/À) mice. Consistent to increased apoptosis, the level of P-BAD decreased in the motor cortex of Cln2 (À/ À) mice ( Fig. 4c and d) . However, treatment of Cln2 (À/À) mice with gem, but not vehicle, led to up-regulation of P-BAD ( Fig. 4c and d) . To understand whether the effect of gem is confined to motor cortex or other part of the brain is also benefitted by gem treatment, we monitored apoptosis in striatum. Similar to motor cortex, we also observed increase in apoptosis (Fig. 5a and b ) and decrease in P-BAD ( Fig. 5c  and d ) in the striatum of Cln2 (À/À) mice. However, gem treatment reduced neuronal apoptosis ( Fig. 5a and b) and increased the level of P-BAD ( Fig. 5c and d) in vivo in the striatum, suggesting that oral gem treatment is capable of suppressing apoptosis in different parts of the brain of Cln2 (À/À) mice.
Gem increases the levels of anti-inflammatory factors in the brain of Cln2 (À/À) mice
We have demonstrated that gem is anti-inflammatory (Pahan et al. 2002; Jana et al. 2007; Jana and Pahan 2012 ) and that gem increases the level of SOCS3 and IL-1Ra, antiinflammatory factors, in different brain cells Ghosh and Pahan 2012b) . Therefore, here, we investigated whether gem treatment could up-regulate these anti-inflammatory molecules in vivo in the brain of Cln2
mice. At 12 weeks of age, we observed decrease in SOCS3 and IL-1Ra in motor cortex ( Fig. 6a and c) and striatum ( Fig. 6d-f ) of Cln2 (À/À) mice as compared to age-matched WT mice. However, after 8 weeks of oral treatment with gem, but not vehicle, the increase in SOCS3 (Fig. 6a, b, d , and e) and IL-1Ra (Fig. 6a, d , c, and f) was seen in both motor cortex and striatum of Cln2 (À/À) mice. To confirm these findings further, next, we performed double-label immunofluorescence in striatal sections. Although we observed more astroglia (Fig. 7a) and microglia (Fig. 7b ) in striatal sections of Cln2 (À/À) mice as compared to WT mice, there was a loss of SOCS3 in the former as compared to the latter (Fig. 7a-c) . However, similar to Western blot results, marked increase in SOCS3 was seen in the striatum of Cln2 (À/À) mice after gem treatment (Fig. 7a-c) . This increase in SOCS3 was visible in astrocytes ( Fig. 7a and d) , microglia ( Fig. 7b and e) as well as other brain cells (Fig. 7) . Similar to SOCS3, we also noticed the loss of IL-1Ra in the striatum of Cln2 (À/À) mice as compared to WT mice ( Fig. 8a-e) . However, treatment of Cln2 (À/À) mice with gem, but not vehicle, led to restoration and/or up-regulation of IL-1Ra in the striatum (Fig, 8a-e) . Again, gem-induced increase in IL-1Ra in vivo in the striatum of Cln2 (À/À) mice was in both astrocytes ( Fig. 8a and d) and microglia ( Fig. 8b  and e) . Interestingly, in both motor cortex and striatum of Cln2 (À/À) mice, we did not observe any reduction in either astroglia or microglia after gem treatment (Figs 7 and 8) , suggesting that once astrogliosis or microgliosis occurs in vivo in the brain of a chronic neurodegenerating condition as found in Cln2 (À/À) mice, gemfibrozil treatment may only modulate their function toward the anti-inflammatory mode without decreasing its number. 
Discussion
Mutations in the Cln2 result in deficiency and/or loss of function of the TPP1 enzyme, ultimately causing LINCL (Sohar et al. 1999; Bellettato and Scarpa 2010; Walus et al. 2010) . Although enzyme replacement therapy and gene therapy clinical trials are ongoing, no established drugmediated therapy is currently available for LINCL. Therefore, development of neuroprotective therapeutic approaches for delaying the disease progression, improving locomotor functions and increasing the survival of LINCL patients are of paramount importance. Cln2 (À/À) mouse is useful in determining new therapeutic strategies and testing the efficacy of new drugs for LINCL. Here, we demonstrate for the first time that gemfibrozil (gem), an FDA-approved drug for hyperlipidemia in humans, improves locomotor functions and prolongs the lifespan in Cln2 (À/À) mice. Recently, we have delineated that gemfibrozil is capable of up-regulating TPP1 in cultured mouse and human brain cells and in vivo in mouse brain via PPARa/RXRa pathway (Ghosh et al. 2012) . However, there is no TPP1 in Cln2 (À/À) mice. Therefore, in this case, gem is employing TPP1-independent mechanisms to delay the disease progression in Cln2 (À/À) mice. Although the importance of autofluorescent storage materials in the pathogenesis of LSDs including LINCL is not known, these inclusion bodies are one of hallmarks of LSDs (Boustany 2013) . Recently, we have also demonstrated that gem is capable of stimulating lysosomal biogenesis via PPARa-mediated transcriptional activation of TFEB (Ghosh et al. 2015) , suggesting possible lowering of storage materials by gem treatment. Accordingly, gem was able to reduce storage materials from the motor cortex of Cln2 (À/À) mice. Therefore, even in the absence of TPP1 (a vital enzyme in the degradation pathway), gem can stimulate autophagic clearance via TFEB-mediated activation of other lysosomal enzymes. Earlier, we have demonstrated that in skin fibroblasts of patients with LINCL, a combination of gemfibrozil and retinoic acid increased lysosomal biogenesis irrespective of the disease status (Ghosh et al. 2015) .
Neuronal apoptosis is a hallmark of most of the known neurodegenerative diseases including lysosomal storage disorders (Lane et al. 1996; Puranam et al. 1997; Dhar et al. 2002) . Strong inhibition of neuronal apoptosis in different parts of the CNS of Cln2 (À/À) mice by gem suggests that this anti-apoptotic property of gem may contribute to its lifespanprolonging efficacy in these mice. BAD, a member of the BCL-2 family, is an important regulator of apoptosis (Datta et al. 1999 (Datta et al. , 2002 . Non-phosphorylated form BAD is known to induce apoptosis by forming heterodimers with survival proteins Bcl-x and Bcl-2, thereby allowing two other proapoptotic proteins, BAK and BAX, to aggregate and induce release of cytochrome c (Datta et al. 1999 (Datta et al. , 2002 . On the other hand, phosphorylated BAD is sequestered in the cytoplasm by binding to 14-3-3 and thereby allowing cell survival. Here, we have demonstrated that gem treatment restores/up-regulates the level of P-BAD in motor cortex and striatum of Cln2 (À/À) mice. Signaling mechanisms leading to phosphorylation of BAD is becoming clear. Phosphatidylinositol-3 kinase (PI3K) is a key signaling molecule implicated in the regulation of a broad array of biological responses including cell survival (Koyasu 2003) . Several studies have shown that activation of PI3K leads to phosphorylation of BAD via Akt (Li et al. 2001; Ellert-Miklaszewska et al. 2005) . Interestingly, gem induces the activation of p85a-associated type IA PI3K in brain cells ). Therefore, it is possible that gem suppresses apoptosis in the CNS of Cln2 (À/À) mice via PI3K -(P)BAD pathway. Although there are many causes of apoptosis in the CNS, neuroinflammation is an important one. Therefore, chronic inflammation mediated by activated glial cells is becoming a hallmark of several neurodegenerative disorders including LINCL (Macauley et al. 2014; Shyng and Sands 2014; Cooper et al. 2015) . IL-1b, a proinflammatory cytokine, is implicated in the pathogenesis of neurodegenerative diseases. Although IL-1b binds to its high-affinity receptor, IL-1R, and up-regulates proinflammatory signaling pathways, IL-1R antagonist (IL-1Ra) adheres to the same receptor and inhibits proinflammatory cell signaling (Basu et al. 2004) . Similarly, suppressor of cytokine signaling (SOCS) proteins also play a crucial role in inhibiting cytokine signaling and inflammatory gene expression in various cell types, including glial cells (Chen et al. 2000; Baker et al. 2009 ). Therefore, up-regulation of IL-1Ra and SOCS is considered important in attenuating inflammation. Recently, we have seen that gem upregulates SOCS3 in glial cells via PI3K-mediated activation of KLF4 (Ghosh and Pahan 2012b) and that gem increases IL-1Ra via PI3K-mediated activation of cAMPresponse element binding protein . It is important to see that gem treatment increased the level of both SOCS3 and IL-1Ra in striatum and cortex of
Cln2
(À/À) mice. Therefore, by up-regulating these important anti-inflammatory molecules, gem may exhibit protection and delay the disease onset in Cln2 (À/À) mice. Gem has several advantages over other prospective neuroprotective agents. For example, gem is an oral drug and fairly non-toxic (Pahan 2006; Backes et al. 2007; Roy and Pahan 2009 ). It has been well tolerated in human and animal studies. Known as 'Lopid' in the pharmacy, it is a commonly used lipid-lowering drug in humans since FDA approval in 1981. The Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) has reported that coronary heart disease events are significantly reduced by gem in patients when the predominant lipid abnormality was low high density lipoprotein cholesterol (HDL-C) (Robins et al. 2001) . In a double-blind, randomized, placebocontrolled trial, this drug was shown to reduce small lowdensity lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A (Superko et al. 2005) . Another recent trial showed that lowdensity lipoprotein and HDL particle subclasses are favorably changed by gem therapy (Otvos et al. 2006) . Gem also lowers triglycerides and raises HDL with reasonable safety in a pediatric population with metabolic syndrome (Smalley and Goldberg 2008) . In summary, we have demonstrated that gemfibrozil, an FDA-approved lipid-lowering drug in humans, reduces storage materials, up-regulates anti-inflammatory molecules, suppresses neuronal apoptosis, and increases the lifespan of Cln2 (À/À) mice. Although in vivo situation of Cln2
(À/À) mouse brain and its treatment with gem may not truly resemble the in vivo neurodegenerative situation in patients with LINCL, our results identify gem as a possible therapeutic agent to prolong the lifespan in LINCL patients.
